https://www.nasdaq.com/press-release/atreca-to-present-anti-sars-cov-2-antibody-discoveries-at-keystone-symposia
https://www.nasdaq.com/press-release/atreca-to-present-at-upcoming-virtual-investor-conferences-2021-11-08
https://www.nasdaq.com/press-release/atreca-reports-third-quarter-2021-financial-results-and-recent-corporate-developments
https://www.nasdaq.com/press-release/atreca-enters-into-licensing-agreement-with-bill-melinda-gates-medical-research
https://www.nasdaq.com/press-release/atreca-announces-poster-presentations-at-the-society-for-immunotherapy-of-cancer-sitc
https://www.nasdaq.com/press-release/atreca-to-present-at-upcoming-virtual-investor-conferences-2021-09-08
https://www.nasdaq.com/press-release/atreca-reports-second-quarter-2021-financial-results-and-recent-corporate
https://www.nasdaq.com/press-release/atreca-to-present-at-upcoming-virtual-investor-conferences-2021-08-04
https://www.nasdaq.com/press-release/atreca-presents-initial-clinical-data-from-phase-1b-trial-of-atrc-101-in-select
https://www.nasdaq.com/press-release/atreca-to-host-webcast-presentation-of-initial-clinical-data-from-phase-1b-trial-of
https://www.nasdaq.com/press-release/atreca-announces-appointment-of-dr.-stacey-ma-and-stephen-r.-brady-to-its-board-of
https://www.nasdaq.com/press-release/atreca-to-present-at-upcoming-virtual-investor-conferences-2021-05-14
https://www.nasdaq.com/press-release/atreca-reports-first-quarter-2021-financial-results-and-recent-corporate-developments
https://www.nasdaq.com/press-release/atreca-to-present-at-upcoming-virtual-investor-conferences-2021-04-06
https://www.nasdaq.com/press-release/atreca-announces-poster-presentation-at-the-virtual-american-association-for-cancer
https://www.nasdaq.com/press-release/atreca-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent
https://www.nasdaq.com/press-release/atreca-to-participate-at-upcoming-virtual-investor-conferences-2021-02-22
https://www.nasdaq.com/press-release/atreca-reports-third-quarter-2020-financial-results-and-recent-corporate-developments
https://www.nasdaq.com/press-release/atreca-to-present-at-upcoming-virtual-investor-conferences-2020-11-06
https://www.nasdaq.com/press-release/atreca-announces-poster-presentations-at-the-2020-society-for-immunotherapy-of-cancer
https://www.nasdaq.com/press-release/atreca-to-present-at-two-upcoming-virtual-investor-conferences-2020-09-03
https://www.nasdaq.com/press-release/atreca-reports-second-quarter-2020-financial-results-and-recent-corporate
https://www.nasdaq.com/press-release/atreca-to-present-at-two-upcoming-virtual-healthcare-conferences-2020-08-05
https://www.nasdaq.com/press-release/atreca-inc.-announces-pricing-of-underwritten-public-offering-of-common-stock-2020-07
https://www.nasdaq.com/press-release/atreca-inc.-announces-proposed-underwritten-public-offering-of-class-a-common-stock
https://www.nasdaq.com/press-release/xencor-and-atreca-enter-strategic-collaboration-to-discover-develop-and-commercialize
https://www.nasdaq.com/press-release/atreca-and-xencor-enter-strategic-collaboration-to-discover-develop-and-commercialize
https://www.nasdaq.com/press-release/atreca-announces-webinar-to-present-atrc-101-preclinical-data-update-on-monday-june
https://www.nasdaq.com/press-release/atreca-announces-appointment-of-kristine-m.-ball-to-its-board-of-directors-2020-05-21
https://www.nasdaq.com/press-release/atreca-reports-first-quarter-2020-financial-results-and-recent-corporate-developments
https://www.nasdaq.com/press-release/atreca-announces-poster-presentation-at-the-american-society-of-clinical-oncology
https://www.nasdaq.com/press-release/atreca-announces-participation-in-the-2020-rbc-capital-markets-virtual-global
https://www.nasdaq.com/press-release/atreca-announces-participation-in-two-upcoming-virtual-investor-conferences-2020-04
https://www.nasdaq.com/press-release/atreca-reports-fourth-quarter-and-full-year-2019-financial-results-2020-03-11
https://www.nasdaq.com/press-release/atreca-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-2020-02
https://www.nasdaq.com/press-release/atreca-announces-first-patient-dosed-in-phase-1b-clinical-trial-of-atrc-101-in
https://www.nasdaq.com/press-release/atreca-announces-strategic-research-collaboration-with-merck-to-identify-novel
https://www.nasdaq.com/press-release/atreca-announces-fda-clearance-of-investigational-new-drug-application-for-atrc-101
https://www.nasdaq.com/press-release/atreca-to-present-at-two-upcoming-investor-conferences-2019-11-14
https://www.nasdaq.com/press-release/atreca-reports-third-quarter-2019-financial-results-and-recent-corporate-developments
